HER2-Positive and Negative Breast Cancer GUIDELINES Pocket Guide

Approved By

American Society of Clinical Oncology

Digital Subscription $4.99 Add to Cart
Print $9.95 Add to Cart
Free Sample

The digital version of the ASCO HER2-Positive and Negative Breast Cancer – Adjuvant Therapy GUIDELINES contains all the same great information found in the pocket guide, and can be accessed on mobile devices and online:

  • ASCO members receive free digital access at www.asco.org/guideline-pocket-cards
  • Price: $4.99
    • Subscribe to additional guideline titles for discounted rates
  • Includes automatic updates during the term of your subscription
  • CPT® and ICD10 codes can be added to certain guidelines for an additional fee
  • Supported platforms
    • iPhone and iPad
    • Android phones and tablets
    • Online (internet connection required)
  • Content on the Guideline Central mobile app accessible without an internet connection
    • Access to additional guideline summaries, clinical calculators, and more

For mobile access, download the free app from the App Store or Google Play and use the same email address and password as the website to login.

For individual use only; contact us for group and site licenses.

The Breast Cancer HR2 – Adjuvant GUIDELINES Pocket Guide is based on the latest guidelines of the American Society of Clinical Oncology and was developed with their collaboration. It contains recommendations for adjuvant treatment of HER2 positive and negative breast cancer.

  • Trifold
  • 6 Pages
  • 80# Diamond Silk Cover with Satin Aqueous Coating
  • 4.25″ x 7.25″
  • Key Points 
  • Treatment Recommendations 
    • Use of an Anthracycline-Taxane Regimen
    • Optimal-Dose Anthracycline Regimen for Patients for Whom a Taxane Is Contraindicated
    • Adding Gemcitabine or Capecitabine to an Anthracycline-Taxane Regimen
    • Capecitabine in Patients Age ≥65 Years
    • Cyclophosphamide-Methotrexate-Fluorouracil As an Alternative To Doxorubicin-Cyclophosphamide
    • Acceptable Adjuvant Chemotherapy Regimens for Patients with Higher-Risk Early Breast Cancer
    • Adjuvant Regimen When an Anthracycline Is Not Preferred
    • Patient Selection and Adjuvant Trastuzumab Therapy
    • Trastuzumab Plus Chemotherapy in Patients with Higher-Risk Her2-Positive Disease
    • Trastuzumab Plus Chemotherapy in Patients with Her2-Positive T1a-B N0 Disease
    • Selection of Chemotherapy Regimens in Patients Receiving Trastuzumab
    • Use of Trastuzumab and an Anthracycline-Containing Regimen
    • Concurrent Administration of Adjuvant Trastuzumab and Non-Anthracycline Chemotherapy Regimens
    • Trastuzumab-Based Chemotherapy or Trastuzumab Regimens For Patients at Higher Risk of Cardiotoxicity
    • Addition of Trastuzumab to Chemotherapy Regimens Not Evaluated in a Phase III Trial
    • Duration of Trastuzumab Therapy and Cardiac Function

Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

  • Guideline Pricing

  • Single Title
    $4.99 / year
  • Any 5 Titles
    $23.99 / year
  • Any 10 Titles
    $41.99 / year
  • Any 35 Titles
    $74.99 / year
  • All Available Titles
    $169.99 / year

To get started, log in or create your free account Create Account